• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
YANG Qian, MA Qiujuan, WANG Xiaojian. Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example[J]. Journal of China Pharmaceutical University, 2015, 46(4): 499-503. DOI: 10.11665/j.issn.1000-5048.20150419
Citation: YANG Qian, MA Qiujuan, WANG Xiaojian. Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example[J]. Journal of China Pharmaceutical University, 2015, 46(4): 499-503. DOI: 10.11665/j.issn.1000-5048.20150419

Suggestions for secondary innovations and generic development for drugs from the perspective of patent — taking HIV protease inhibitor lopinavir as an example

More Information
  • Protease inhibitors(PIs)are a class of antiviral drugs widely used for the treatment of HIV/AIDS. The status of intellectual property of HIV protease inhibitors lopinavir is briefly reviewed in this paper. Based on the indication of Kaletra® , the follow-up studies and generic development of PIs were discussed. It was concluded that the combination of PIs and anti-bacterial/anti-fungal drugs with CYP450 inhibitory effects would be of great use for AIDS and the infectious complications, in the hope of seeking the secondary innovation of other drugs with expired patents in the fields of drug combination and indication expansion.
  • [1]
    Yang QG,He XC,Bai DL.Current status of HIV protease inhibitors[J].Acta Pharm Sin(药学学报),2005,40(5):389-394.
    [2]
    Guo DL, Liu GN, Li J, et al. Improved synthesis of raltegravir[J].J China Pharm Univ(中国药科大学学报),2009,40(4):297-301.
    [3]
    Molla A,Mo HM,Vasavanonda S,et al.In vitro antiviral interaction of lopinavir with other protease inhibitors[J].Antimicrob Agents Ch,2002,46(7):2249-2253.
    [4]
    Liu J,Dong L.The discussion of generic drugs development for Chinese pharmaceutical enterprises[J].Chin Pharm(中国药业),2011,20(16):6-7.
    [5]
    Guo ZR,Zhao HY.Challenges and strategies of drug innovation[J].Acta Pharm Sin(药学学报),2013,48(7):1031-1040.
    [6]
    Aids Map.Fixed-dose combinations[EB/OL].(2011-03-31)[2014-04-09] .http://www.aidsmap.com/Fixed-dosecombinations/page/1729748/.
    [7]
    Walmsley S.Protease inhibitor-based regimens for HIV therapy:safety and efficacy[J].J Acq Imm Def Syn,2007,45(S1):S5-13.
    [8]
    Du HZ,Yang Q,Song JY,et al.Research toward approved drugs for anti-HIV/acquired immunodeficiency syndrome and its complications[J].Chin Pharm J(中国药学杂志),2009,44(2):81-87.
    [9]
    U.S.Food and Drug Administration.Drug development and drug interactions:table of substrates,inhibitors and inducers[EB/OL].(2006-05-01)[2014-05-20] .http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#classInhibit.
    [10]
    Sanso G.Double capsule for the administration of active principles in multiple therapies:US,6350486B1[P].2002-02-26[2014-05-25] .
    [11]
    Wu JJ,Stranix BR,Ge M,et al.Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors:US,2012/0053139A1[P].2012-05-01[2014-05-25] .
  • Related Articles

    [1]SHEN Yunhong, CHEN Hongjie, MAO Zewei, HUANG Zhengxiao, HU Chunyan. Synthesis and antifungal evaluation of chalcone derivatives combined with fluconazole against drug-resistant Candida albicans[J]. Journal of China Pharmaceutical University, 2023, 54(5): 564-568. DOI: 10.11665/j.issn.1000-5048.2023041002
    [2]Gao Zhonghao. 新型药物递送系统技术在药物研发中的应用和展望[J]. Journal of China Pharmaceutical University, 2023, 54(1): 1-4. DOI: 10.11665/j.issn.1000-5048.2023030303
    [3]YANG Wanwan, YE Fangyu, WU Yujia, WANG Haochen, ZHAO Li. Research progress of PARP inhibitors in cancers and their drug resistance[J]. Journal of China Pharmaceutical University, 2022, 53(5): 525-534. DOI: 10.11665/j.issn.1000-5048.20220503
    [4]BAO Xingjia, CHEN Xin, WANG Shiru, LING Yunni, ZHANG Jianjun, GAO Yuan. Coamorphous combinations of poorly water-soluble drugs dabigatran etexilate mesylate and tadalafil for improving dissolution and physical stability[J]. Journal of China Pharmaceutical University, 2019, 50(5): 549-559. DOI: 10.11665/j.issn.1000-5048.20190507
    [5]SHI Jinyu, BAI Ying, PENG Kewen, ZHANG Wenhui, ZHU Qihua, XU Yungen. Research progress of PARP-1 inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2019, 50(5): 523-530. DOI: 10.11665/j.issn.1000-5048.20190503
    [6]JIA Chengshu, WANG Junwei, LI Hui, ZHU Qihua, GE Yiran, XU Yungen. Advances of phosphoinositide-3 kinase inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2017, 48(5): 523-528. DOI: 10.11665/j.issn.1000-5048.20170503
    [7]CHEN Jiajia, BEI Yuncheng, ZHANG Dongmei, SHEN Pingping. Combination of artemether with etoposide inhibits cell proliferation and invasion in small cell lung cancer cell line H446[J]. Journal of China Pharmaceutical University, 2017, 48(2): 201-207. DOI: 10.11665/j.issn.1000-5048.20170211
    [8]JIANG Yuqiu, TANG Qiaofei, ZHANG Shuang, YAN Zhiyong. Combined effects of gallic acid and ciprofloxacin on the murine chronic rhinosinusitis model in mice[J]. Journal of China Pharmaceutical University, 2015, 46(5): 600-604. DOI: 10.11665/j.issn.1000-5048.20150514
    [9]HE Junjin, WANG Jiayi, HAO Jingchao, CHENG Haoran, XU Hanmei. Antitumor effect of peptide mPEG-SC20k-HM-3 and oxaliplatin combination against human hepatocellular carcinoma SMMC-7721 in nude mice[J]. Journal of China Pharmaceutical University, 2015, 46(4): 476-480. DOI: 10.11665/j.issn.1000-5048.20150415
    [10]WU Keqin. Antitumor activity and mechanism of saikosaponin D combined with oxaliplatin on A549 cells-bearing nude mice[J]. Journal of China Pharmaceutical University, 2015, 46(3): 355-358. DOI: 10.11665/j.issn.1000-5048.20150316
  • Cited by

    Periodical cited type(2)

    1. 任红梅,熊晔蓉,荀校莹,姜雷,涂家生. 新型含铝疫苗佐剂的研究进展. 中国药科大学学报. 2025(02): 236-243 . 本站查看
    2. 袁明城,张剑,陈洋,薛潘,武福星,袁若栋,董阳超,徐志凯,张芳琳,雷迎峰. 仙台病毒递送新型冠状病毒RBD蛋白鼻内免疫接种增强呼吸道黏膜和系统性免疫应答的初步研究. 空军军医大学学报. 2023(07): 609-614 .

    Other cited types(1)

Catalog

    Article views (1200) PDF downloads (2934) Cited by(3)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return